{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:13:31Z","timestamp":1761488011799},"reference-count":14,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The efficacy of rifalazil and other benzoxazinorifamycins was tested in a mouse model of lung infection against\n            <jats:italic>Chlamydia pneumoniae<\/jats:italic>\n            . Rifalazil and six related new chemical entities all showed efficacy after one dose per day for 3 days at either 3 or 1 mg\/kg of body weight.\n          <\/jats:p>","DOI":"10.1128\/aac.01567-07","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T00:51:03Z","timestamp":1205196663000},"page":"1855-1858","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Benzoxazinorifamycins in a Mouse Model of\n            <i>Chlamydia pneumoniae<\/i>\n            Lung Infection"],"prefix":"10.1128","volume":"52","author":[{"given":"Lee Ann","family":"Campbell","sequence":"first","affiliation":[{"name":"Departments of Pathobiology and Epidemiology, University of Washington, Seattle, Washington 98195"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cho-Chou","family":"Kuo","sequence":"additional","affiliation":[{"name":"Departments of Pathobiology and Epidemiology, University of Washington, Seattle, Washington 98195"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Suchland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Rothstein","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., 110 Hartwell Avenue, Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.58.4.686-699.1994"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.5.3027-3029.2006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.2.434-439.1992"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/322632"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1489"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2749"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/21.Supplement_3.S244"},{"key":"e_1_3_2_9_2","first-page":"317","volume":"21","year":"1997","unstructured":"Kuo, C.-C., J. T. Grayston, T. Hidaka, and L. M. Rose. 1997. A comparison of the in vitro sensitivity of Chlamydia pneumoniae to macrolides and a new benzoxazinorifamycin, KRM-1648, p. 317-321. In S. H. Zinner, L. S. Young, J. F. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides, and streptogramins. Infectious disease and therapy series, vol. 21. Marcel Dekker, New York, NY.","journal-title":"Expanding indications for the new macrolides, azalides, and streptogramins."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2006.05465.x"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1135-1136.2003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01087-05"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.6.603"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1120-1126.2005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.636-642.2003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01567-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01567-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:37:06Z","timestamp":1645472226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01567-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1128\/AAC.01567-07"],"URL":"https:\/\/doi.org\/10.1128\/aac.01567-07","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"2007-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-02-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}